Burge ME, Espinoza D, Sjoquist KM, Siu DH, Mercieca-Bebber R, Chantrill LA, Karapetis CS, Steer CB, Yip S, Cuff J, Winata S, Tie J, Thaker DA, Srivastav R, Abdi E, Strickland A, Segelov E, Francesconi A, Price T, Ladwa R, Joubert W, Tebbutt NC. AGITG MONARCC: A Randomized Phase 2 Study of Panitumumab Monotherapy and Panitumumab Plus 5-Fluorouracil as First-Line Therapy for Older Patients With RAS and BRAF Wild Type Metastatic Colorectal Cancer. A Study by the Australasian Gastro-Intestinal Trials Group (AGITG). Clinical Colorectal Cancer. 2025;24(2):10.1016/j.clcc.2024.11.003
Tie J, Wang Y, Loree JM, Cohen JD, Espinosa D, Wong R, Price TJ, Tebbutt NC, Lee M, Burge ME, Harris SJ, Lee B, Lynam JF, O’Callaghan CJ, Breadner DA, Bettegowda C, Papadopoulos N, Kinzler KW, Vogelstein B, Gibbs P. ctDNA-guided adjuvant chemotherapy escalation in stage III colon cancer: Primary analysis of the ctDNA-positive cohort from the randomized AGITG dynamic-III trial (intergroup study of AGITG and CCTG).Journal of Clinical Oncology. 2025;43(16_suppl):10.1200/jco.2025.43.16_suppl.3503
McLachlan S-A, Mostafa R, Sharpe L, Burge ME, Day F, Blum RH, Campbell R, Lynam JF, Lee B, Singh MS, Lee M, Chantrill LA, Lundy J, Wong ZW, Wong R, Joshi S, Saqib A, Karikios DJ, Gibbs P, Tie J. Circulating tumor DNA (ctDNA) analysis guiding adjuvant therapy in patients (pts) with colorectal cancer (CRC): Impact on fear of cancer recurrence (FCR).Journal of Clinical Oncology. 2025;43(16_suppl):10.1200/jco.2025.43.16_suppl.11125
Chantrill LA, Samra JS, Tebbutt NC, Nikfarjam M, Reid D, Brungs D, Jaber M, Tie J, Mendis SR, Hong W, Cavicchiolo T, Cuff J, Hayes SJ, Christophersen LC, Roesner M, Maloney S. Neo-adjuvant chemo-immunotherapy in pancreatic cancer: Results of the Australasian Gastrointestinal Trials Group (AGITG) NEO-IMPACT pilot trial.Journal of Clinical Oncology. 2025;43(16_suppl):10.1200/jco.2025.43.16_suppl.4189
Tie J, Melian M, Ruiz-Casado A, Wyrwicz L, Wysocki PJ, Stuebs P, Aranda E, Salas N, Elez E, Curigliano G, Radecka B, Parseghian C, Takacs I, Heinemann V, Vandal G, Huniti N, Vidal Barrul J. Phase 1 dose escalation results of the WEE1 inhibitor, azenosertib (A), in combination with encorafenib (E) and cetuximab (C) in patients (pts) with previously treated BRAF V600E mutantmetastatic colorectal cancer (mCRC).Journal of Clinical Oncology. 2025;43(16_suppl):10.1200/jco.2025.43.16_suppl.3551
Shi Q, Chang GJ, Pederson LD, Asare EA, Jin Z, Cohen R, Meyerhardt JA, Andre T, Tie J, Dixon JG, Palis BE, Ballman KV, Yothers G, Ma Z, Alberts SR, Shi C, Washington MK, Taieb J, Steele S, Goldberg RM. Proposed changes to the pathologic staging for colon cancer (CC): AJCC Colon Cancer Expert Panel (AJCCCCEP).Journal of Clinical Oncology. 2025;43(16_suppl):10.1200/jco.2025.43.16_suppl.3520
Tie J, Wang Y, Lo SN, Lahouel K, Cohen JD, Wong R, Shapiro JD, Harris SJ, Khattak A, Burge ME, Lee M, Harris M, McLachlan S-A, Horvath L, Karapetis C, Shannon J, Singh M, Yip D, Ananda S, Underhill C, Ptak J, Silliman N, Dobbyn L, Popoli M, Papadopoulos N, Tomasetti C, Kinzler KW, Vogelstein B, Gibbs P. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial. Nature Medicine. 2025;31(5):10.1038/s41591-025-03579-w
Kim GY, Tie J, Gibbs P. Letter to the Editor: Are We Asking the Right Question for New Biomarkers – “Ready for Prime Time” Versus Demonstrated Clinical Utility?. Journal of the National Comprehensive Cancer Network. 2025;23(5):10.6004/jnccn.2025.7037
Samnotra V, Ramos-Hernandez N, Faitg T, Srinivasan M, Roy T, Liu A, Zaremba T, Holford C, Smith R, Henry JT, Tie J, Yamamoto N, Serbest G. Abstract CT194: First-in-human, phase 1/2 study of GSK4418959, an oral Werner DNA helicase inhibitor, alone or combined with other anticancer agents in adults with advanced mismatch repair-deficient or microsatellite instability-high solid tumors (SYLVER). Cancer Research. 2025;85(8_Supplement_2):10.1158/1538-7445.am2025-ct194
Siena S, Raghav K, Takashima A, Kato T, Van den Eynde M, Pietrantonio F, Komatsu Y, Kawakami H, Peeters M, Andre T, Lonardi S, Yamaguchi K, Tie J, Castro CG, Strickler JH, Shiose Y, Koga M, Boran A, Haribhai D, Goto H, Barrios D, Abe K, Yoshino T. Abstract 7148: Exploratory biomarker analysis of trastuzumab deruxtecan (T-DXd) treatment for HER2-positive (HER2+) metastatic colorectal cancer (mCRC) in DESTINY-CRC02 (DC-02). Cancer Research. 2025;85(8_Supplement_1):10.1158/1538-7445.am2025-7148
